LOUISVILLE, Colo. - Biodesix, Inc. (NASDAQ:BDSX), a company specializing in diagnostic solutions for lung disease, has announced a new collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop diagnostic tests for cancer treatment. The partnership, formalized through a master collaborative research agreement (MCRA), will leverage Biodesix's expertise in genomics, proteomics, and data mining, alongside Bio-Rad's digital PCR technology.
The collaboration aims to advance the development and commercialization of oncology biomarker assays. Representatives from both institutions, Dr. Howard Scher from MSK and Dr. Gary Pestano from Biodesix, shared insights into the industry-academic collaboration at the 31st International Precision Medicine Tri-Con meeting today.
Scott Hutton, CEO of Biodesix, remarked on the significance of evolving their previous agreement with MSK into the MCRA, highlighting the potential for co-developing and validating new test concepts in oncology diagnostics. Similarly, Simon May, EVP and President of Life Sciences at Bio-Rad Laboratories (NYSE:BIO), expressed enthusiasm for the joint effort to create next-generation digital PCR assays as part of their expanding oncology portfolio.
Biodesix is known for its focus on lung disease and utilizes artificial intelligence to combine multi-omics in developing diagnostic tests. The company currently offers five Medicare-covered tests for lung disease, including the Nodify Lung® Nodule Risk Assessment testing strategy and the IQLung™ strategy for lung cancer patients, which facilitate rapid treatment decisions.
This collaboration is poised to enhance the precision and efficacy of cancer diagnostics, although the press release contains forward-looking statements that involve risks and uncertainties. The company has based these statements on current expectations, which are subject to change.
The information in this article is based on a press release statement from Biodesix.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.